A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.
about
Chemotherapy-induced peripheral neurotoxicity: a critical analysisDose schedule optimization and the pharmacokinetic driver of neutropeniaPhase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors.A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trialEffects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in womA study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia.Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer.Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxelRandomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.Refining docetaxel-containing therapy for gastric cancer.A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer.The role of taxanes in the treatment of breast cancer.Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II study.Docetaxel in the treatment of breast cancer: current experience and future prospects.Role of chemotherapy in breast cancer.Docetaxel-associated epiphora.Recent advances in targeted therapies for colorectal cancer.Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancerThe new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies.Safety and efficacy of single-agent docetaxel (Taxotere) administered weekly in non-small cell lung carcinoma patients in Korea: An observational study.A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study.Antiangiogenic properties of metronomic chemotherapy in breast cancer.Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.Weekly docetaxel in the treatment of metastatic breast cancer.Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review.Optimal use of taxanes in metastatic breast cancerStrategies to decrease taxanes toxicities in the adjuvant treatment of early breast cancer.Single premedication dose of dexamethasone 20 mg IV before docetaxel administration.Dexamethasone premedication for prophylaxis of taxane toxicities: can the doses be reduced when paclitaxel or docetaxel are given weekly?Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.Metabolism of the taxanes including nab-paclitaxel.Awareness of the adverse effects associated with prophylactic corticosteroid use during docetaxel therapy.Results of 20- versus 45-min post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia.Treatment regimens of classical and newer taxanes.Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis.Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel.Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
P2860
Q27010318-B3AF2383-4D8B-4C9F-B11A-2258E86BA54EQ28544635-333AA46D-171D-43A7-A6B2-107200EB7EC0Q33368139-32D1E31F-E8EC-4D39-B0A6-1B87626E7F0BQ33378865-1618099C-341C-4F88-9AE5-7C73DA262430Q33399824-00BAF9EF-9D7D-49C2-A36D-5A11EB9CDBC6Q33821528-1C9284E5-E3A2-43D1-9EB5-32AE92C27B49Q33904763-8AE3FDBA-0B2F-4F2B-9E1B-1CC279861154Q34136875-523A47CD-CE26-4977-9E94-D4770D6F7309Q34271252-0F02D358-6BC4-4BB4-BD73-CD1DF249BA54Q34458581-5652B0FC-EE21-4542-AC7A-FE635D419EC1Q34464827-8C4E2AFC-07DA-41D3-BACC-35E63BF51F06Q34640591-FEADEF6F-48C0-4E8A-A545-EA919CB079A9Q35445166-BEC6C3E8-6844-4209-BBE6-31A00B0BA76EQ36070770-5304D304-4A91-4AC6-830F-C146C3E9C5E9Q36163956-15B6C1ED-D920-40B9-B3D3-9FECB387A021Q36195479-A374007C-D387-4EB4-8B62-6232FBBB93BFQ36235546-15F5240E-2A5D-42CF-8DAF-519340FE62E7Q36334921-474A96B4-2718-41E3-BE94-124E304AFF9BQ36484970-DE5AFEF5-6590-422A-9CB8-F5A2E43D9573Q36597888-A913F10A-2F72-4E75-B57F-67EFF573B1B1Q36614337-46049995-96BA-4CF9-9480-4EF77D49FCA1Q36634272-6020D7F6-0E7B-44AD-AAD1-305E08A7E963Q36636822-DC782597-D4B9-4E1D-B5CB-5BE1323F5431Q36695252-F0C98027-049D-4A4C-9F38-7ED5F20FA031Q36768296-12974383-7FF7-4CC2-AEF6-9D761D35C12CQ36879127-5B315DDC-5411-448E-92B8-42E68F4E20DEQ37052871-FA36B6CE-C714-4B2C-B64A-77CD75A19BCFQ37161450-3EDEC6E5-5BC6-49CF-82C7-2000B5E762A5Q37225780-F38A5FA7-3C06-4344-8A2D-C323115990F7Q37398926-603DF22D-7166-4F86-BD90-BC23FEE2193FQ37744191-F6A80574-C1D8-4F78-8B90-92A40E82D809Q37909780-D388B667-39A8-41B3-9FE2-412DFAC9C8F1Q37957744-DB30FDDE-B84E-44E9-B432-F48E06773151Q38267987-7CD79E0F-EC47-4045-943F-F4CB5C9EC719Q38286988-2FF444F6-4AD6-491C-BDB9-06AFDBFDA8AAQ38396811-A67CF3D8-3B65-4E53-8F7A-4040E74F0BBDQ38641136-9B7536B9-44C0-416D-8022-A664870C26C0Q38946259-BE2164C3-22CF-4392-88B9-F02D7B441F18Q40521965-3500A05A-2B75-4C7E-B0FB-796B49DC5537Q46528079-08B6B31F-B26E-4D18-A254-4CEBD1A92121
P2860
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
A multicentre, randomised phas ...... with metastatic breast cancer.
@en
A multicentre, randomised phas ...... with metastatic breast cancer.
@nl
type
label
A multicentre, randomised phas ...... with metastatic breast cancer.
@en
A multicentre, randomised phas ...... with metastatic breast cancer.
@nl
prefLabel
A multicentre, randomised phas ...... with metastatic breast cancer.
@en
A multicentre, randomised phas ...... with metastatic breast cancer.
@nl
P2093
P356
P1433
P1476
A multicentre, randomised phas ...... with metastatic breast cancer.
@en
P2093
A Barnadas
J Albanell
J B Vermorken
J Garcia-Conde
J I Mayordomo
J L Tisaire
P304
P356
10.1093/ANNONC/MDH349
P577
2004-09-01T00:00:00Z